Nuvalent, Inc. (NUVL)

NASDAQ: NUVL · IEX Real-Time Price · USD
76.64
+0.90 (1.19%)
At close: Mar 27, 2024, 4:00 PM
71.17
-5.47 (-7.14%)
After-hours: Mar 27, 2024, 4:49 PM EDT
1.19%
Market Cap 4.91B
Revenue (ttm) n/a
Net Income (ttm) -126.22M
Shares Out 64.07M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 282,703
Open 76.85
Previous Close 75.74
Day's Range 75.54 - 77.60
52-Week Range 23.10 - 89.39
Beta 1.36
Analysts Strong Buy
Price Target 79.29 (+3.46%)
Earnings Date May 9, 2024

About NUVL

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Ph... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 29, 2021
Employees 92
Stock Exchange NASDAQ
Ticker Symbol NUVL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price forecast is $79.29, which is an increase of 3.46% from the latest price.

Price Target
$79.29
(3.46% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

22 days ago - PRNewsWire

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

Well-capitalized with operating runway anticipated into 2027 CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ --  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on crea...

4 weeks ago - PRNewsWire

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

CAMBRIDGE, Mass. , Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

4 weeks ago - PRNewsWire

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-655 of 150 mg once daily Phase 2 Designed with Registrational Intent for TKI Pre-Treated Patients with ALK-Positive...

6 weeks ago - PRNewsWire

Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

7 weeks ago - PRNewsWire

Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones

Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer Well-capitalized to support OnTarget 2026 initiatives wit...

2 months ago - PRNewsWire

Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. , Dec. 21, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

3 months ago - PRNewsWire

Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

Presented preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655, initiated Phase 2 portion of ARROS-1 trial of NVL-520, and continued advancement of NVL-330 toward clinical development Appo...

4 months ago - PRNewsWire

Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day

CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

5 months ago - PRNewsWire

Nuvalent Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Oct. 16, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

5 months ago - PRNewsWire

Nuvalent Announces Public Offering of Common Stock

CAMBRIDGE, Mass. , Oct. 16, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

5 months ago - PRNewsWire

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

Encouraging preliminary signs of activity observed in heavily pre-treated patients with ALK-positive NSCLC, including in subgroups of patients who have previously received a 2nd generation ALK TKI and...

5 months ago - PRNewsWire

Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile

Updated preliminary data to be presented at the 35th AACR-NCI-EORTC Symposium Company plans to host a conference call on October 13, 2023 at 8:00am EDT CAMBRIDGE, Mass. , Oct. 4, 2023 /PRNewswire/ -- ...

6 months ago - PRNewsWire

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass. , Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creat...

6 months ago - PRNewsWire

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors

Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-520 of 100 mg daily CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stag...

7 months ago - PRNewsWire

Nuvalent to Participate in Upcoming September Investor Conferences

CAMBRIDGE, Mass. , Aug. 31, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

7 months ago - PRNewsWire

Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results

Continued execution across pipeline with clinical trials ongoing for NVL-520 and NVL-655, and advancement of NVL-330 toward clinical development Preliminary dose-escalation data anticipated from ongoi...

8 months ago - PRNewsWire

Nuvalent to Participate in Upcoming August Investor Conferences

CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

8 months ago - PRNewsWire

Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

CAMBRIDGE, Mass. , May 24, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...

11 months ago - PRNewsWire

Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

Preliminary dose-escalation data anticipated in second half of 2023 from ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors Stron...

11 months ago - PRNewsWire

Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days

CAMBRIDGE, Mass. , April 19, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas...

1 year ago - PRNewsWire

Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023

CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...

1 year ago - PRNewsWire

Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)

CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas...

1 year ago - PRNewsWire

Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Significant progress made across pipeline of novel kinase inhibitors with parallel-lead programs in ongoing Phase 1 clinical trials and a third program advancing toward clinical development   Strength...

1 year ago - PRNewsWire

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023

CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas...

1 year ago - PRNewsWire